PedAM
Pediatric Disease Annotations & Medicines
| Disease | prostate cancer |
| Phenotype | C0948265|metabolic syndrome |
| Sentences | 11 |
| PubMedID- 22022057 | [17] the association between metabolic syndrome and risk of prostate cancer was stronger among overweight and obese men with a bmi ≥ 27 kg/m2 (adjusted relative risk, 3.0; 95% ci, 1.2-7.3) than in lighter men (relative risk, 1.8; 95% ci, 0.7-4.7). |
| PubMedID- 24935591 | The metabolic syndrome is associated with more aggressive prostate cancer. |
| PubMedID- 22883053 | metabolic syndrome increases the risk of aggressive prostate cancer detection. |
| PubMedID- 24516490 | [1213] affecting the metabolism and endocrine function of patients with prostate cancer, adt can lead to metabolic syndrome. |
| PubMedID- 25755679 | Higher ages and lower high-density lipoprotein-cholesterol were two parameters that were significant only in the prostate cancer group with metabolic syndrome. |
| PubMedID- 23060995 | prostate cancer in patients with metabolic syndrome is associated with low grade gleason score when diagnosed on biopsy. |
| PubMedID- 24368236 | Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer. |
| PubMedID- 24360772 | metabolic syndrome in patients with prostate cancer undergoing androgen suppression. |
| PubMedID- 25541340 | Purpose: androgen deprivation therapy may promote the development of the metabolic syndrome in patients with prostate cancer. |
| PubMedID- 26275075 | metabolic syndrome components are associated with increased prostate cancer risk. |
| PubMedID- 24552491 | Therefore, several mechanisms could explain the association of obesity and metabolic syndrome with prostate cancer pathogenesis, including sex steroid hormone, insulin and insulin-like growth factors and inflammation pathways [6,57-59]. |
Page: 1